Austrália - inglês - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 36 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - cabotegravir, quantity: 30 mg (equivalent: cabotegravir sodium, qty mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; macrogol 3350 - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna <50 copies/ml) and have no known or suspected resistance to either cabotegravir or rilpivirine (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties, clinical trials) for: ? oral lead in to assess tolerability of cabotegravir prior to administration of cabotegravir prolonged-release suspension for injection plus rilpivirine prolonged-release suspension for injection. ? oral therapy for adults who will miss planned dosing with cabotegravir prolonged-release suspension for injection.

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - ivabradine oxalate -

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - ivabradine oxalate -

União Europeia - inglês - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Estados Unidos - inglês - NLM (National Library of Medicine)

abraxis bioscience, llc - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel 100 mg in 20 ml - abraxane is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. abraxane is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. abraxane is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. abraxane is contraindicated in patients with: risk summary based on its mechanism of action and findings in animals, abraxane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available human data on abraxane use in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of paclitaxel formul

Israel - inglês - Ministry of Health

neopharm scientific ltd - paclitaxel - powder for suspension for infusion - paclitaxel 100 mg/vial - paclitaxel - abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

União Europeia - inglês - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv infections - antivirals for systemic use - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna

Israel - inglês - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 150 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.